dinoprost and Intestinal-Pseudo-Obstruction

dinoprost has been researched along with Intestinal-Pseudo-Obstruction* in 2 studies

Other Studies

2 other study(ies) available for dinoprost and Intestinal-Pseudo-Obstruction

Article	Year
Prostaglandin F2 alpha in the treatment of vinca alkaloid-induced ileus. The American journal of medicine, 1993, Volume: 95, Issue:5 Topics: Aged; Dinoprost; Female; Humans; Intestinal Pseudo-Obstruction; Lung Neoplasms; Male; Middle Aged; Vinca Alkaloids	1993
Response to octreotide of intestinal pseudoobstruction and pneumatosis cystoides intestinalis associated with progressive systemic sclerosis. Internal medicine (Tokyo, Japan), 1993, Volume: 32, Issue:7 Intestinal pseudoobstruction and pneumatosis cystoides intestinalis are uncommon complications of progressive systemic sclerosis. We report a 26-year-old woman with this disorder who responded poorly to conventional treatment. Subcutaneous administration of octreotide, a long-acting somatostatin analogue, at a dose of 50 micrograms/day for 3 weeks, relieved symptoms such as nausea and bloating. There was also a marked decrease of intestinal gas accumulation, as documented on X-ray films. Topics: Adult; Combined Modality Therapy; Dinoprost; Domperidone; Female; Gastrointestinal Motility; Humans; Intestinal Pseudo-Obstruction; Octreotide; Pneumatosis Cystoides Intestinalis; Scleroderma, Systemic	1993

Article

Year

Prostaglandin F2 alpha in the treatment of vinca alkaloid-induced ileus.

The American journal of medicine, 1993, Volume: 95, Issue:5

Topics: Aged; Dinoprost; Female; Humans; Intestinal Pseudo-Obstruction; Lung Neoplasms; Male; Middle Aged; Vinca Alkaloids

1993

Response to octreotide of intestinal pseudoobstruction and pneumatosis cystoides intestinalis associated with progressive systemic sclerosis.

Internal medicine (Tokyo, Japan), 1993, Volume: 32, Issue:7

Intestinal pseudoobstruction and pneumatosis cystoides intestinalis are uncommon complications of progressive systemic sclerosis. We report a 26-year-old woman with this disorder who responded poorly to conventional treatment. Subcutaneous administration of octreotide, a long-acting somatostatin analogue, at a dose of 50 micrograms/day for 3 weeks, relieved symptoms such as nausea and bloating. There was also a marked decrease of intestinal gas accumulation, as documented on X-ray films.

Topics: Adult; Combined Modality Therapy; Dinoprost; Domperidone; Female; Gastrointestinal Motility; Humans; Intestinal Pseudo-Obstruction; Octreotide; Pneumatosis Cystoides Intestinalis; Scleroderma, Systemic

1993